ArticlePharmacoEconomics2020

Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.

Ning Kam et al.PubMed ↗Publisher ↗

No numbers read from the abstract.